71 related articles for article (PubMed ID: 37200112)
1. Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab.
McMinn ME; Brister KA; Orr WS; Sheehan NT; Christopher WO
Am Surg; 2024 Mar; ():31348241241642. PubMed ID: 38553440
[TBL] [Abstract][Full Text] [Related]
2. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
Hegewisch-Becker S; Mendez G; Chao J; Nemecek R; Feeney K; Van Cutsem E; Al-Batran SE; Mansoor W; Maisey N; Pazo Cid R; Burge M; Perez-Callejo D; Hipkin RW; Mukherjee S; Lei M; Tang H; Suryawanshi S; Kelly RJ; Tebbutt NC
J Clin Oncol; 2024 May; ():JCO2301636. PubMed ID: 38723227
[TBL] [Abstract][Full Text] [Related]
3. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Schuler M; Cuppens K; Plönes T; Wiesweg M; Du Pont B; Hegedus B; Köster J; Mairinger F; Darwiche K; Paschen A; Maes B; Vanbockrijck M; Lähnemann D; Zhao F; Hautzel H; Theegarten D; Hartemink K; Reis H; Baas P; Schramm A; Aigner C
Nat Med; 2024 Apr; ():. PubMed ID: 38689060
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in malignant melanoma: recent approaches and new perspectives.
Arasanz H; Lacalle A; Lecumberri MJ; de Lascoiti ÁF; Blanco-Luquin I; GatoCañas M; Pérez-Ricarte L; Zuazo M; Kochan G; Escors D
Melanoma Manag; 2017 Mar; 4(1):39-48. PubMed ID: 30190903
[TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
Wu LW; Tao JJ; McDonnell D; Izar B
Melanoma Res; 2024 Apr; ():. PubMed ID: 38640504
[TBL] [Abstract][Full Text] [Related]
7. Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?
van Akkooi ACJ
Ann Surg Oncol; 2024 Jan; 31(1):1-3. PubMed ID: 37843663
[No Abstract] [Full Text] [Related]
8. Project Optimus elicits the "holistic" benefits of PK/PD modeling of immunotherapy.
Gopalakrishnan M; Amaria RN
Clin Cancer Res; 2024 May; ():. PubMed ID: 38743418
[TBL] [Abstract][Full Text] [Related]
9. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-the therapeutic considerations in the clinical practice.
Adeleke S; Okoli S; Augustine A; Galante J; Agnihotri A; Uccello M; Ghose A; Moschetta M; Boussios S
Ann Palliat Med; 2023 Nov; 12(6):1355-1372. PubMed ID: 37431221
[TBL] [Abstract][Full Text] [Related]
11. Relatlimab-nivolumab: A practical overview for dermatologists.
Mullick N; Nambudiri VE
J Am Acad Dermatol; 2023 Nov; 89(5):1031-1037. PubMed ID: 37343829
[TBL] [Abstract][Full Text] [Related]
12. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
[TBL] [Abstract][Full Text] [Related]
13. Pathology and Molecular Biology of Melanoma.
Timis T; Bergthorsson JT; Greiff V; Cenariu M; Cenariu D
Curr Issues Mol Biol; 2023 Jun; 45(7):5575-5597. PubMed ID: 37504268
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
Koseła-Paterczyk H; Rutkowski P
Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
[TBL] [Abstract][Full Text] [Related]
15. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL; Reeves DJ
Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab and relatlimab for the treatment of melanoma.
Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
[TBL] [Abstract][Full Text] [Related]
19. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]